Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?

Ürün, Yüksel; Yasar, H Arzu; Turna, Hande; Kiliçkap, Saadettin; Sezer, Ahmet; Öksüzoglu, Berna; Özdemir, Nuriye; Sendur, Ma Nahit; Abali, Hüseyin

Ürün, Yüksel; Yasar, H Arzu; Turna, Hande; Kiliçkap, Saadettin; Sezer, Ahmet; Öksüzoglu, Berna; Özdemir, Nuriye; Sendur, Ma Nahit; Abali, Hüseyin.

Afiliação

Ürün Y; Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Yasar HA; Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Turna H; Cerrahpasa Medical Faculty, Medical Oncology, Istanbul Univesity, Istanbul, Turkey.
Kiliçkap S; Faculty of Medicine, Medical Oncology, Hacettepe University, Ankara, Turkey.
Sezer A; Adana Hospital, Medical Oncology, Baskent University, Adana, Turkey.
Öksüzoglu B; Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Medical Oncology, Ankara, Turkey.
Özdemir N; Faculty of Medicine, Medical Oncology, Gazi University, Ankara, Turkey.
Sendur MN; Faculty of Medicine, Medical Oncology, Yildirim Beyazit University, Ankara, Turkey.
Abali H; Medical Oncology, Adana Acibadem Hospital, Adana, Turkey.

J Oncol Pharm Pract ; 25(8): 2062-2063, 2019 12.

Article em En | MEDLINE | ID: mdl-31226917

Assuntos

Imunoterapia; Melanoma; Terapia Combinada; Humanos; Ipilimumab; Prognóstico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoterapia / Melanoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google